Ras family of small GTPases in immunity and inflammation
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The Ras superfamily of small GTPases is a group of more than 150 small G proteins, all of which share some degree of homology to the founding member Ras. These small GTPases function as molecular switches within cells, impacting nearly all cellular processes. The Ras superfamily can be further divided into several smaller subfamilies, with those proteins that most closely resemble Ras belonging to the Ras subfamily. While heavily studied within the field of cancer biology, the Ras family of proteins also plays cardinal roles in immunity and inflammation. Here we review the roles of these molecular switches in regulating immune cell homeostasis and functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The sequential activity of the GTPases Rap1B and Cdc42 determines neuronal polarity.
Schwamborn, J. C., & Püschel, A. W. (2004) · Nature Neuroscience · doi:10.1038/nn1295 · Cited by 385 · cited 1×
“Rap1 has been implicated in the activation of integrin-mediated adhesion [15,16], establishment of polarity [17,18], cell proliferation, and the control of cell–cell interactions [19].”
BackgroundA role for mammalian target of rapamycin in regulating T cell activation versus anergy
Zheng, Y., Collins, S. L., Lutz, M. A., Allen, A. N., Kole, T. P., Zarek, P. E., & Powell, J. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2163 · Cited by 274 · cited 1×
“The downstream PI3K target mTOR determines whether T cells become activated or undergo anergy [11].”
Background
Cited by
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 944
Polyphenols as Antitumor Agents Targeting Key Players in Cancer-Driving Signaling Pathways
Cháirez-Ramírez, M. H., de la Cruz-López, K. G., & García-Carrancá, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.710304 · Cited by 231
“RAS represents a family of GTPases composed of 150 G-proteins (HRAS, KRAS, and NRAS) and represents the first actors in the MAPK/ERK phosphorylation cascade (Johnson and Chen, 2012).”
BackgroundYou, Y., Borgmann, K., Edara, V. V., Stacy, S., Ghorpade, A., & Ikezu, T. (2020) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1706801 · Cited by 176
“The small GTPases cluster enriched in IL-1βADEVs, which play an important role in cytoskeletal reorganization, signal transduction, cell invasion, cellular interaction and inflammation, may explain how ADEVs could modulate neuritogenesis and synaptogenesis [39].”
BackgroundRal signaling pathway in health and cancer
Moghadam, A. R., Patrad, E., Tafsiri, E., Peng, W., Fangman, B., Pluard, T. J., Accurso, A., Salacz, M., Shah, K., Ricke, B., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1105 · Cited by 58
“Likewise, Ral binds to Sec5 and Exo84, and subsequently recruits exocyst function that is necessary for different cellular pathways such as polarized exocytosis, cytokinesis, cell migration, ciliogenesis, and wound healing [96, 97].”
BackgroundTørresen, O. K., Brieuc, M. S. O., Solbakken, M. H., Sørhus, E., Nederbragt, A. J., Jakobsen, K. S., Meier, S., Edvardsen, R. B., & Jentoft, S. (2018) · BMC Genomics · doi:10.1186/s12864-018-4616-y · Cited by 46
Metadata
- Authors
- Johnson, D. S., & Chen, Y. H.
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 12
- Issue
- 4
- Pages
- 458-463
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W2010919030
- Cited by
- 117
- References
- 2
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.